Ann: Information For Retail Shareholders, page-152

but the companies "strategic position" would alter significantly with favourable outcome/s from the multiple conversations with the fda in the next quarter.
feedback on assays for bla
pathways for heart failure and heart disease
and ghvd adults protocol

All those things in the next quarter sounds exciting.

Just one arising question though:

"Why are they wanting to raise all this money now, at record lows with all the associated dilutuon, instead of just waiting a few months until some of those "favourable outcomes" manifest themselves, and they would be able to raise capital at a higher price that reflects the significant change in the "strategic position"?

.